impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Reviews

 

COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?

1, 2, 3, 4, 5, 6, 7, 8

 

  1. Rheumatology Unit, ASST-Fatebenefratelli L. Sacco University Hospital, University of Milan, Italy. piercarlo.sarziputtini@gmail.com
  2. Rheumatology Unit, ASST-Fatebenefratelli L. Sacco University Hospital, University of Milan, Italy.
  3. Rheumatology Unit, ASST-Fatebenefratelli L. Sacco University Hospital, University of Milan, Italy.
  4. Rheumatology Unit, ATS Sardegna, P. Dettori Hospital, Tempio Pausania, Italy.
  5. Gastrointestinal Unit, ASST-Fatebenefratelli Sacco. L. Sacco Department of Biochemical and Clinical Sciences, University of Milan, Italy.
  6. Department of Infectious Diseases, I Division of Infectious Diseases ASST Fatebenefratelli-Sacco, Milan, Italy.
  7. Department of Biomedical and Clinical Sciences 'Luigi Sacco', University of Milan, and III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.
  8. Department of Biomedical and Clinical Sciences 'Luigi Sacco', University of Milan, and III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.

CER13350
2020 Vol.38, N°2
PI 0337, PF 0342
Reviews

Free to view
(click on article PDF icon to read the article)

PMID: 32202240 [PubMed]

Received: 21/03/2020
Accepted : 21/03/2020
In Press: 22/03/2020
Published: 26/03/2020

Abstract

A severe outbreak of coronavirus disease 2019 (COVID-19) emerged in China in December 2019, and spread so rapidly that more than 200,000 cases have so far been reported worldwide; on January 30, 2020, the WHO declared it the sixth public health emergency of international concern. The two previously reported coronavirus epidemics (severe acute respiratory syndrome [SARS] and Middle East respiratory syndrome [MERS]) share similar pathogenetic, epidemiological and clinical features as COVID-19. As little is currently known about SARS-CoV-2, it is likely that lessons learned from these major epidemics can be applied to the new pandemic, including the use of novel immunosuppressive drugs.

DOI: https://doi.org/10.55563/clinexprheumatol/xcdary

Rheumatology Article